Synonyms: D2E7 [6] | Humira®
adalimumab is an approved drug (FDA (2002), EMA (2003))
Compound class:
Antibody
Comment: Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [6]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively). Biosimilars:
View more information in the IUPHAR Pharmacology Education Project: adalimumab |
Immunopharmacology Comments |
Adalimumab is an anti-TNFα immunosuppresive drug. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Anti-TNFα monoclonal antibody therapy approved for RA | |
Ankylosing spondylitis |
Disease Ontology:
DOID:7147 |
Anti-TNFα monoclonal antibody therapy approved for ankylosing spondylitis. | |
Psoriasis |
Disease Ontology:
DOID:8893 |
Anti-TNFα monoclonal antibody therapy approved for psoriatic arthritis and plaque psoriasis. | |
Crohn's disease |
Disease Ontology:
DOID:8778 OMIM: 266600 Orphanet: ORPHA206 |
Anti-TNFα monoclonal antibody therapy approved for Crohn's disease. |